




Searching News Database: ruxolitinib
HSMN NewsFeed - 26 May 2020
Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive Officer
Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive Officer
HSMN NewsFeed - 9 Mar 2018
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
HSMN NewsFeed - 22 Oct 2012
Jim Daly to Join Incyte as Executive Vice President and Chief Commercial Officer
Jim Daly to Join Incyte as Executive Vice President and Chief Commercial Officer
HSMN NewsFeed - 15 Mar 2011
Incyte’s Ruxolitinib (INCB18424) Meets Primary Endpoint in Second Phase III Study
Incyte’s Ruxolitinib (INCB18424) Meets Primary Endpoint in Second Phase III Study